Protagonist Therapeutics, Inc. (PTGX) Q4 2020 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to Protagonist Therapeutics' fourth and full year 2020 earnings conference call and audio webcast. At this time, all participants are in a listen-only mode. Please be advised that today's webcast is being recorded. If you require any further assistance, please press star zero. With that, I would like to hand the conference over to our first speaker, Don Kalkofen, Chief Financial Officer. Thank you, and please go ahead. Thank you for joining us today. Thank you. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the risk factor sections of our annual report on Form 10-K for the year ended December 31, 2020, on file with the SEC. A question and answer session will follow the formal presentation. And just as a reminder, the call is being recorded. I'd now like to turn the call over to Dinesh Patel, President and CEO of Protagonist, to provide a company update. Thank you, Don. Good afternoon, everyone, and thank you all for joining our conference call to discuss protagonist therapeutics, financial results, and corporate highlights for the fourth quarter and full year 2020. Don and I are joined on today's call by Samuel Sachs, our Chief Medical Officer, David Liu, our Chief Scientific Officer, and Sunil Gupta, Chief was an exceptional and transformative year for Protagonist, during which we expanded our clinical pipeline, and we now have five different new chemical entities, or NCEs, that are being advanced in six different clinical studies. And all of these studies are expected to be completed over the next two years. As many of you know, each of our clinical assets has been developed through our proprietary technology platform, an...